Conduit Pharmaceuticals (CDT) announces an agreement with Charles River Laboratories (CRL) to evaluate AZD1656 in a clinically relevant Systemic Lupus Erythematosus model. This collaboration highlights Conduit’s focus on generating high-quality preclinical data to optimize the development pathway for its clinical program in auto-immune and position itself for success in its upcoming Phase II clinical trials.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDT:
- Conduit announces debt repayment, conversion of senior secured note
- 3 Penny Stocks to Watch Now, 2/11/25
- Biotech Alert: Searches spiking for these stocks today
- Conduit Pharmaceuticals transitions to Phase II of Sarborg collan
- Conduit Pharmaceuticals files to sell 5.9M shares of common stock for holders